science
Meta-analysis finds tirzepatide produced largest weight loss among three GLP-1 drugs
A University of Georgia review of 14,000 non-diabetic patients showed tirzepatide led to more than 20 percent body-weight reduction, compared with roughly 15 percent for semaglutide and 8 percent for liraglutide.
.jpg)
thequint.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A University of Georgia meta-analysis compared weight-loss results among three GLP-1 medications in 14,000 non-diabetic patients. Tirzepatide produced the largest average loss, exceeding 20 percent of starting body weight. Semaglutide produced losses near 15 percent, and liraglutide produced losses near 8 percent.
Mechanism and dosing Tirzepatide activates both GLP-1 and GIP receptors, while the other two drugs target GLP-1 receptors alone. The review found the highest doses of tirzepatide delivered the strongest results without increased reports of nausea or gastrointestinal side effects.
Study limits The analysis did not track weight changes after patients stopped treatment or separate outcomes between injectable and oral forms. Separate clinical trials have shown oral versions produce smaller losses than injections. D. student at the UGA College of Pharmacy.
Transparency
1 source · single source
CorroborationModerate · 1 source
